MedPath

Pyxis Oncology

Pyxis Oncology logo
🇺🇸United States
Ownership
Public
Established
2019-01-01
Employees
50
Market Cap
$216.9M
Website
http://www.pyxisoncology.com
Introduction

Pyxis Oncology, Inc. engages in the business of developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. The firm focuses on the development of product candidates to directly kill tumor cells and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. The company was founded by David Steinberg, Shaan C. Gandhi, and John L. Flavin on June 11, 2018 and is headquartered in Boston, MA.

Clinical Trials

5

Active:2
Completed:0

Trial Phases

1 Phases

Phase 1:5

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials

Phase 1
5 (100.0%)

Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors

Phase 1
Recruiting
Conditions
Advanced Solid Tumours
Interventions
First Posted Date
2025-01-28
Last Posted Date
2025-06-24
Lead Sponsor
Pyxis Oncology, Inc
Target Recruit Count
200
Registration Number
NCT06795412
Locations
🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

University of Texas - M.D. Anderson Cancer Center, Houston, Texas, United States

🇺🇸

NEXT Virginia, Fairfax, Virginia, United States

Study of PYX-201 in Solid Tumors

Phase 1
Recruiting
Conditions
Advanced Solid Tumor
Solid Tumor
Interventions
First Posted Date
2023-02-09
Last Posted Date
2025-02-06
Lead Sponsor
Pyxis Oncology, Inc
Target Recruit Count
120
Registration Number
NCT05720117
Locations
🇺🇸

HonorHealth Research Institute, Scottsdale, Arizona, United States

🇺🇸

SCRI - HealthOne Denver, Denver, Colorado, United States

🇺🇸

SCRI - Florida Cancer Specialists, Sarasota, Florida, United States

and more 15 locations

Study of PYX-106 in Solid Tumors

Phase 1
Active, not recruiting
Conditions
Solid Tumor
Interventions
First Posted Date
2023-02-08
Last Posted Date
2025-05-01
Lead Sponsor
Pyxis Oncology, Inc
Target Recruit Count
47
Registration Number
NCT05718557
Locations
🇺🇸

HonorHealth Research Institute, Scottsdale, Arizona, United States

🇺🇸

University of California San Diego, La Jolla, California, United States

🇺🇸

University of Southern California, Los Angeles, California, United States

and more 17 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.